My Smoke Wholesale's 777 Jackpot Alkaloids tablets are adulterated dietary supplements because 7-OH lacks adequate safety information.
What happened
FDA reviewed the labeling for 777 Jackpot Alkaloids, 18 mg tablets in various flavors and found it declares 7-hydroxymitragynine (7-OH) as a dietary ingredient. FDA says 7-OH is a new dietary ingredient because there is no information showing it was marketed as a dietary ingredient in the U.S. before October 15, 1994. FDA concluded there is inadequate information to provide reasonable assurance that 7-OH does not present a significant or unreasonable risk of illness or injury.
What FDA found
The product contains 7-hydroxymitragynine (7-OH), a new dietary ingredient for which there is inadequate information to provide reasonable assurance that it does not present a significant or unreasonable risk of illness or injury, so the supplement is adulterated.
Section 402(f)(1)(B) of the Act (21 U.S.C. 342(f)(1)(B))The company introduces or delivers the adulterated dietary supplement into interstate commerce, which the Act prohibits.
Section 301(a) of the ActThe labeling declares 7-OH as a dietary ingredient, and FDA treats 7-OH as a new dietary ingredient because no information shows it was marketed as a dietary ingredient in the U.S. before October 15, 1994.
Section 413(d) of the Act (21 U.S.C. 350b(d)); section 201(ff)(1)(F) (21 U.S.C. 321(ff)(1)(F))
What FDA wants
FDA asks My Smoke Wholesale to notify it in writing within 15 working days of the steps taken to address the violations, including an explanation of steps to prevent recurrence and copies of related documentation. If corrective actions cannot be completed in that time, the company must state the reason for delay and when it will finish; if it believes the products are not in violation, it must include its reasoning and supporting information.
Who should pay attention
- retailers and distributors selling 7-OH dietary supplements
- brands that use 7-OH in supplement products
- consumers using kratom-derived or 7-OH products
This is a summary. Read the original letter on fda.gov.